Compare Bitdeer Technologies Group (BTDR) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bitdeer Technologies Group vs Merck & Co., Inc. — how do they compare? Bitdeer Technologies Group trades at $9.05 (market cap $2.36B), while Merck & Co., Inc. trades at $132.66 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 136.3× Bitdeer Technologies Group's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Bitdeer Technologies Group pays none. Which is the better fit depends on your goals.
| BTDR | MRK | |
|---|---|---|
Market Cap | $2.36B | $321.77B |
Sector | Technology | Health |
52-Week High | $25.90 | $132.93 |
52-Week Low | $7.28 | $77.60 |
Enterprise Value | $3.85B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTDR trades at $9.02, up 3.74% in the last session, with a bearish technical signal from moving averages and oscillators. The company reported Q2 2026 revenue of $812 million but a net loss of $229 million, missing EPS estimates for four consecutive quarters. Recent news highlights a $4.7 billion AI data center deal in Norway, expanding beyond Bitcoin mining, though gross margins remain pressured.
Outlook is mixed: strong analyst buy consensus (81.82%) and a $22.43 price target suggest upside, but persistent losses, negative cash flow from operations, and high dependency on volatile crypto markets pose significant risks. Investors should weigh growth potential in AI infrastructure against execution challenges and profitability concerns.
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue reached $65.01B in 2025, and net income margin improved to 28.07%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, supported by analyst consensus favoring a buy rating (67.57%) and a price target of $140.36. Key opportunities include pipeline expansion through M&A and solid cash flow generation. Risks involve high valuation multiples, such as a P/E of 104.34, and potential integration challenges from acquisitions. Investors should weigh growth prospects against elevated earnings expectations and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bitdeer Technologies Group
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
